Researchers find mechanism that fosters development of neuroendocrine prostate cancer, identify a dual-drug treatment that slowed tumor growth in lab tests A new study has uncovered promising ...

177Lu-vipivotide tetraxetan PSMA vs cabazitaxel in metastatic castration-resistant prostate cancer: A real-world analysis using the TriNetX database. This is an ASCO Meeting Abstract from the 2025 ...

Neuroendocrine prostate cancer (NEPC) is the most aggressive form of prostate cancer, responsible for up to 20% of therapy-resistant cases and associated with rapid disease progression. It is ...

ARV-766, a proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): Initial results of a phase 1/2 study. Nivolumab and ...

Many clinicians who treat men with prostate cancer may be unfamiliar with the term "treatment-emergent small-cell neuroendocrine prostate cancer" (t-SCNC). That's because it has been considered a rare ...

After canceling a planned advisory committee meeting, the FDA has approved Exelixis’ Cabometyx for neuroendocrine tumors. The small-molecule drug is now allowed for patients 12 years of age and older ...

Among men worldwide, prostate cancer is the second most common cancer and the fifth leading cause of cancer deaths. As the world's population ages, the number of prostate cancer patients is expected ...

It is not unusual for advanced prostate cancer to become resistant to treatment. Of these resistant cases, some progress to a specific form of the disease, which is particularly aggressive and deadly.

A new study has uncovered promising therapeutic strategies against one of the deadliest forms of prostate cancer. McGill University researchers at the Rosalind and Morris Goodman Cancer Institute (GCI ...